Evolutionary Tree Capital Management LLC Sells 4,497 Shares of Krystal Biotech, Inc. $KRYS

Evolutionary Tree Capital Management LLC cut its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 26.8% during the 1st quarter, Holdings Channel reports. The fund owned 12,314 shares of the company’s stock after selling 4,497 shares during the period. Krystal Biotech comprises approximately 6.0% of Evolutionary Tree Capital Management LLC’s investment portfolio, making the stock its 3rd largest position. Evolutionary Tree Capital Management LLC’s holdings in Krystal Biotech were worth $3,181,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Royal Bank of Canada increased its stake in Krystal Biotech by 145.2% in the first quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock valued at $294,000 after purchasing an additional 964 shares in the last quarter. AQR Capital Management LLC raised its holdings in shares of Krystal Biotech by 29.9% during the first quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock valued at $2,187,000 after purchasing an additional 2,792 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Krystal Biotech by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock worth $2,870,000 after purchasing an additional 688 shares in the last quarter. Empowered Funds LLC bought a new position in shares of Krystal Biotech during the 1st quarter worth about $218,000. Finally, Cetera Investment Advisers grew its stake in shares of Krystal Biotech by 107.9% in the 2nd quarter. Cetera Investment Advisers now owns 4,344 shares of the company’s stock valued at $597,000 after buying an additional 2,255 shares during the period. 86.29% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

KRYS has been the subject of a number of research analyst reports. Weiss Ratings lowered Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, July 1st. HC Wainwright increased their price target on Krystal Biotech from $310.00 to $361.00 and gave the stock a “buy” rating in a report on Tuesday, June 16th. Evercore reissued an “outperform” rating and issued a $300.00 price objective on shares of Krystal Biotech in a research note on Tuesday, May 5th. Wall Street Zen downgraded Krystal Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Finally, Bank of America boosted their price objective on Krystal Biotech from $364.00 to $396.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Ten analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $360.67.

Krystal Biotech Trading Down 7.0%

Krystal Biotech stock opened at $341.12 on Friday. The firm has a market capitalization of $10.06 billion, a price-to-earnings ratio of 45.60 and a beta of 0.50. The firm’s fifty day moving average price is $339.70 and its two-hundred day moving average price is $296.28. Krystal Biotech, Inc. has a 1-year low of $130.50 and a 1-year high of $382.54.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, May 4th. The company reported $1.83 EPS for the quarter, topping the consensus estimate of $1.45 by $0.38. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. The company had revenue of $116.36 million during the quarter, compared to the consensus estimate of $112.11 million. On average, research analysts forecast that Krystal Biotech, Inc. will post 7.31 EPS for the current year.

Insider Activity

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the completion of the transaction, the insider owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. The trade was a 1.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $347.27, for a total value of $347,270.00. Following the sale, the executive vice president directly owned 1,000 shares of the company’s stock, valued at $347,270. This represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 26,642 shares of company stock worth $8,243,923. 13.10% of the stock is owned by insiders.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.